Iowa Governor Signs Bill Limiting Mail-Order Abortions
Iowa Governor Kim Reynolds has enacted legislation that restricts the ability to obtain mail-order abortions. The new law, referred to as House File 2788, prohibits the prescription of abortion-inducing medication, particularly mifepristone, through telemedicine or mail services. Instead, prescriptions must be issued in person.
This law will take effect on July 1, coinciding with ongoing legal battles in Louisiana against the U.S. Food and Drug Administration (FDA) concerning a policy that previously permitted the mailing of abortion pills in light of a Supreme Court decision related to abortion rights.
Mifepristone, which the FDA first approved in 2000, had specific safety regulations that mandated in-person prescriptions and visits. Over the years, those requirements have loosened, especially after the Biden administration made significant changes in 2021, solidifying the move away from in-person prescriptions in 2023, which many viewed as a challenge to restrictive state laws.
Recent legal developments have further complicated the landscape. For instance, a lawsuit in Louisiana claims that FDA policies were enacted without proper legal protocols, specifically criticizing the easing of safeguards surrounding mifepristone.
A panel from the U.S. Court of Appeals for the Fifth Circuit had previously ruled against the FDA’s 2023 policy, suggesting that the Biden administration’s actions aimed to undermine pro-life legislation following the Supreme Court’s ruling in the Dobbs case.
In a related context, pharmaceutical companies are appealing to the Supreme Court, citing immediate economic repercussions from these changes. The court recently permitted the continued mailing of abortion pills while the legal dispute is resolved, although conservative justices, including Samuel Alito and Clarence Thomas, expressed dissent. Thomas pointed out potential violations of the Comstock Act regarding the transport of abortion-inducing drugs.
The ongoing legal proceedings may eventually require further review from the Supreme Court.
Related: Report Projects 1.1 Million Abortions by 2025; Rise in Telemedicine Abortions
The Guttmacher Institute estimates that in 2023 medication abortions represented about 63% of all abortions in the U.S. This is a notable increase from previous years. However, this report does not account for drugs acquired through unregulated networks that often supply individuals in states with stricter abortion laws.
Additionally, pro-abortion advocates anticipate that telemedicine will facilitate around 91,000 abortions in 2025 for those in states with restrictions, aided by protective laws from more liberal states.
In terms of medical abortion procedures, mifepristone works by blocking progesterone, a hormone necessary for sustaining pregnancies, ultimately leading to the termination of the pregnancy through subsequent medication, misoprostol, which induces contractions and expulsion.
